Effect of cilostazol in patients with intermittent claudication

A randomized, double-blind, placebo-controlled study

D. Eugene Strandness, Ronald L. Dalman, Steve Panian, Marc S. Rendell, Philip C. Comp, Peter Zhang, William P. Forbes

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

A multicenter, double-blind, randomized, placebo-controlled, parallel study was conducted to compare the efficacy and safety of cilostazol 100 mg and 50 mg, both administered twice daily, with that of placebo in patients with moderately severe intermittent claudication (IC) secondary to peripheral arterial disease. A total of 394 subjects 40 years of age or older with chronic, stable, symptomatic IC received cilostazol 100 mg twice daily, 50 mg twice daily, or placebo for 24 weeks. Subjects receiving cilostazol 100 mg twice daily experienced a 21% net improvement in maximal walking distance (MWD) compared with placebo subjects (p = 0.0003) and a 22% net improvement in distance walked to the onset of symptoms (PFWD) (p = 0.0015). Subjects who received cilostazol 50 mg twice daily also benefited from therapy, but not to a statistically significant degree (7% and 11% improvement in MWD and PFWD, respectively). Quality-of-life and functional status assessments corroborated these objective results. Cilostazol, in particular 100 mg twice daily, significantly improves symptoms in patients with IC.

Original languageEnglish
Pages (from-to)83-91
Number of pages9
JournalVascular and Endovascular Surgery
Volume36
Issue number2
StatePublished - Mar 2002

Fingerprint

Intermittent Claudication
Placebos
Walking
Peripheral Arterial Disease
Quality of Life
cilostazol
Safety

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Strandness, D. E., Dalman, R. L., Panian, S., Rendell, M. S., Comp, P. C., Zhang, P., & Forbes, W. P. (2002). Effect of cilostazol in patients with intermittent claudication: A randomized, double-blind, placebo-controlled study. Vascular and Endovascular Surgery, 36(2), 83-91.

Effect of cilostazol in patients with intermittent claudication : A randomized, double-blind, placebo-controlled study. / Strandness, D. Eugene; Dalman, Ronald L.; Panian, Steve; Rendell, Marc S.; Comp, Philip C.; Zhang, Peter; Forbes, William P.

In: Vascular and Endovascular Surgery, Vol. 36, No. 2, 03.2002, p. 83-91.

Research output: Contribution to journalArticle

Strandness, DE, Dalman, RL, Panian, S, Rendell, MS, Comp, PC, Zhang, P & Forbes, WP 2002, 'Effect of cilostazol in patients with intermittent claudication: A randomized, double-blind, placebo-controlled study', Vascular and Endovascular Surgery, vol. 36, no. 2, pp. 83-91.
Strandness, D. Eugene ; Dalman, Ronald L. ; Panian, Steve ; Rendell, Marc S. ; Comp, Philip C. ; Zhang, Peter ; Forbes, William P. / Effect of cilostazol in patients with intermittent claudication : A randomized, double-blind, placebo-controlled study. In: Vascular and Endovascular Surgery. 2002 ; Vol. 36, No. 2. pp. 83-91.
@article{5b6adf45aee648c59be5ae6d2c746f1e,
title = "Effect of cilostazol in patients with intermittent claudication: A randomized, double-blind, placebo-controlled study",
abstract = "A multicenter, double-blind, randomized, placebo-controlled, parallel study was conducted to compare the efficacy and safety of cilostazol 100 mg and 50 mg, both administered twice daily, with that of placebo in patients with moderately severe intermittent claudication (IC) secondary to peripheral arterial disease. A total of 394 subjects 40 years of age or older with chronic, stable, symptomatic IC received cilostazol 100 mg twice daily, 50 mg twice daily, or placebo for 24 weeks. Subjects receiving cilostazol 100 mg twice daily experienced a 21{\%} net improvement in maximal walking distance (MWD) compared with placebo subjects (p = 0.0003) and a 22{\%} net improvement in distance walked to the onset of symptoms (PFWD) (p = 0.0015). Subjects who received cilostazol 50 mg twice daily also benefited from therapy, but not to a statistically significant degree (7{\%} and 11{\%} improvement in MWD and PFWD, respectively). Quality-of-life and functional status assessments corroborated these objective results. Cilostazol, in particular 100 mg twice daily, significantly improves symptoms in patients with IC.",
author = "Strandness, {D. Eugene} and Dalman, {Ronald L.} and Steve Panian and Rendell, {Marc S.} and Comp, {Philip C.} and Peter Zhang and Forbes, {William P.}",
year = "2002",
month = "3",
language = "English",
volume = "36",
pages = "83--91",
journal = "Vascular and Endovascular Surgery",
issn = "1538-5744",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Effect of cilostazol in patients with intermittent claudication

T2 - A randomized, double-blind, placebo-controlled study

AU - Strandness, D. Eugene

AU - Dalman, Ronald L.

AU - Panian, Steve

AU - Rendell, Marc S.

AU - Comp, Philip C.

AU - Zhang, Peter

AU - Forbes, William P.

PY - 2002/3

Y1 - 2002/3

N2 - A multicenter, double-blind, randomized, placebo-controlled, parallel study was conducted to compare the efficacy and safety of cilostazol 100 mg and 50 mg, both administered twice daily, with that of placebo in patients with moderately severe intermittent claudication (IC) secondary to peripheral arterial disease. A total of 394 subjects 40 years of age or older with chronic, stable, symptomatic IC received cilostazol 100 mg twice daily, 50 mg twice daily, or placebo for 24 weeks. Subjects receiving cilostazol 100 mg twice daily experienced a 21% net improvement in maximal walking distance (MWD) compared with placebo subjects (p = 0.0003) and a 22% net improvement in distance walked to the onset of symptoms (PFWD) (p = 0.0015). Subjects who received cilostazol 50 mg twice daily also benefited from therapy, but not to a statistically significant degree (7% and 11% improvement in MWD and PFWD, respectively). Quality-of-life and functional status assessments corroborated these objective results. Cilostazol, in particular 100 mg twice daily, significantly improves symptoms in patients with IC.

AB - A multicenter, double-blind, randomized, placebo-controlled, parallel study was conducted to compare the efficacy and safety of cilostazol 100 mg and 50 mg, both administered twice daily, with that of placebo in patients with moderately severe intermittent claudication (IC) secondary to peripheral arterial disease. A total of 394 subjects 40 years of age or older with chronic, stable, symptomatic IC received cilostazol 100 mg twice daily, 50 mg twice daily, or placebo for 24 weeks. Subjects receiving cilostazol 100 mg twice daily experienced a 21% net improvement in maximal walking distance (MWD) compared with placebo subjects (p = 0.0003) and a 22% net improvement in distance walked to the onset of symptoms (PFWD) (p = 0.0015). Subjects who received cilostazol 50 mg twice daily also benefited from therapy, but not to a statistically significant degree (7% and 11% improvement in MWD and PFWD, respectively). Quality-of-life and functional status assessments corroborated these objective results. Cilostazol, in particular 100 mg twice daily, significantly improves symptoms in patients with IC.

UR - http://www.scopus.com/inward/record.url?scp=0036522391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036522391&partnerID=8YFLogxK

M3 - Article

VL - 36

SP - 83

EP - 91

JO - Vascular and Endovascular Surgery

JF - Vascular and Endovascular Surgery

SN - 1538-5744

IS - 2

ER -